Climate change remains dangerous. Emissions are too high. Grids are behind. Permitting is slow. Mining has consequences. Energy security can still pull governments back toward gas, coal and old habits. But deployment changes the fight. Costs fall. Workers learn. Utilities adapt. Voters begin to understand clean energy as jobs, bills, security and ordinary life rather than sermon or sacrifice.
Medicine gives the same argument a human face. Victoria Gray was three months old when she would not stop crying. Blood tests brought the diagnosis: sickle-cell disease, a genetic illness that can turn blood cells into little instruments of pain. Gray later described the pain as “getting struck by lightning and hit by a truck.” She spent years in and out of hospitals and often missed her children’s birthdays.²
In 2019, at thirty-four, Gray became the first patient with sickle-cell disease to receive an experimental CRISPR-based therapy. Doctors collected her blood stem cells, edited them outside her body, used chemotherapy to make room in her bone marrow and infused the edited cells back into her. Four years later, the FDA approved Casgevy, the first FDA-approved treatment using CRISPR/Cas9, for patients twelve and older with sickle-cell disease and recurrent vaso-occlusive crises.³
“It felt like an answered prayer for me,” Gray later said. “CRISPR not only freed me, it freed my children.”⁴
That sentence carries more weight than the word breakthrough. A scientific achievement became family time. It became birthdays not spent in the hospital. The treatment remains difficult, expensive and far too hard to get. Even so, we are now fighting over who gets access to a thing that used to be impossible.
The same pattern is showing up in public health. Malaria still kills far too many children, and vaccines alone will not end it. But the world now has two WHO-recommended malaria vaccines, RTS,S and R21.⁵ In Cameroon, eighteen-month-old twins, Daniel and Daniella, were the first children in the country to receive the malaria vaccine when routine vaccination began there in January 2024. Their mother, Hélène Akono, later told Gavi, “My twins are so lucky.” Since vaccination, she said, they had not suffered from malaria.⁶
That is the scale at which progress actually reaches people: two children, one clinic, one mother, one disease that did not arrive.
Artificial intelligence belongs in this record, though it comes wrapped in more noise and less humility. The public face of AI is often chatbots, fake images, cheating, job fear, copyright fights and the manufacture of unreality at scale. Those problems are real. AI is also doing quieter work.
AlphaFold, developed by Google DeepMind and EMBL’s European Bioinformatics Institute, predicts a protein’s three-dimensional structure from its amino-acid sequence. Its database now provides open access to more than 200 million protein-structure predictions.⁷ For scientists trying to understand disease, design drugs or study enzymes that might break down plastic, that kind of map changes the first hour of the work. It helps them begin closer to the right question.
The map still leaves the experiment to be done. That is the honest shape of many advances now. They give judgment better tools while still requiring judgment. The technology is not the future by itself. The future comes from the choices made around it.
The world economy tells the same mixed story. Growth is slow. Debt is heavy.